Atlas Trials

Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)

Clinical trial NCT05115409 · UNKNOWN

Trial details

NCT number
NCT05115409
Sponsor
Sun Yat-sen University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed or Refractory DLBCL
Start date
2022-06-01
Primary completion
2022-12-01
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.